• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

    6/25/25 7:00:00 AM ET
    $GILD
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GILD alert in real time by email

    Gilead Sciences, Inc. (NASDAQ:GILD) and Kymera Therapeutics, Inc. (NASDAQ:KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential including in breast cancer and other solid tumors.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250625261668/en/

    CDK2-directed MGDs are a new type of drug designed to remove CDK2 – a key contributor in tumor growth – rather than just inhibiting its function. Traditional inhibitors of CDK2 prevent it from working but often interfere with similar proteins, which can cause undesired side effects. MGDs have the potential to provide more precise, safe and effective treatments for cancers that rely on CDK2 activity by selectively removing this protein from cells.

    "MGDs are opening exciting new possibilities in cancer research by offering a way to eliminate disease-driving proteins rather than just blocking them. This mechanism aligns within our oncology scientific framework where we evaluate therapeutic agents that selectively target and kill cancer cells with minimal impact on healthy tissue," said Flavius Martin, MD, Executive Vice President, Research, Gilead Sciences. "We are delighted to partner with Kymera to advance this novel oral program with the potential to drive meaningful improvements in the standard of care for patients living with breast cancer and other cancers that are inadequately served with existing therapies."

    "We are excited to announce this strategic collaboration with Gilead Sciences, highlighting our dedication to innovation in the field with our first disclosed molecular glue program. We are committed to developing highly selective, potent, oral degrader medicines that address key disease-causing proteins and pathways that are undrugged or inadequately drugged by existing technologies," said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics. "Our highly specific, orally active, CDK2 molecular glue degraders have demonstrated a compelling preclinical profile and have the potential to transform the therapeutic landscape for breast cancer patients and other tumor types with high unmet medical need. We are excited to work with the talented Gilead team to accelerate the development and commercialization of this important program."

    Terms of the Agreement

    Under the terms of the agreement, Kymera is eligible to receive up to $750 million in total payments, including up to $85 million in upfront and potential option exercise payments. In addition, Kymera may also receive tiered royalties ranging from high single-digit to mid-teens on net product sales under the collaboration. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option to exclusively license the program, Gilead will have global rights to develop, manufacture and commercialize all products resulting from the collaboration.

    Gilead does not exclude acquired IPR&D expenses from its non-GAAP financial measures. This transaction with Kymera is expected to reduce Gilead's GAAP and non-GAAP 2025 EPS by approximately $0.02 - $0.03.

    About Gilead and Kite Oncology

    Gilead and Kite Oncology are working to transform how cancer is treated. We are innovating with next-generation therapies, combinations and technologies to deliver improved outcomes for people with cancer. We are purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody-drug conjugates and small molecules to cell therapy-based approaches, we are creating new possibilities for people with cancer.

    About Gilead Sciences

    Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.

    About Kymera Therapeutics

    Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients' lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston's top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.

    Gilead Forward-Looking Statements

    This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including Gilead's ability to realize the anticipated benefits from the collaboration; difficulties or unanticipated expenses in connection with the collaboration and the potential effects on Gilead's earnings; the ability of the parties to initiate, progress or complete clinical trials within currently anticipated timelines or at all, and the possibility of unfavorable results from ongoing or additional trials, including those involving programs developed pursuant to the collaboration; the ability of the parties to file applications for regulatory approval or receive regulatory approvals in a timely manner or at all for the investigational programs developed pursuant to the collaboration, and the risk that any such approvals may be subject to significant limitations on use; the possibility that the parties may make a strategic decision to discontinue development of any of the investigational programs developed pursuant to the collaboration, and therefore these programs may never be successfully commercialized; and any assumptions underlying any of the foregoing. These and other risks, uncertainties and other factors are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as filed with the U.S. Securities and Exchange Commission. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Kymera‘s expectations regarding strategy, business plans and objectives on the development of CDK2 degraders, Kymera's plans with respect to the potential benefits of and Kymera's expectations with respect to the collaboration with Gilead, the potential achievement of upfront, option exercise, milestone and royalty payments and the extent to which CDK2 degraders generally may address breast cancer and other solid tumors, including the therapeutic potential, clinical benefits and safety thereof. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target," "upcoming" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from any forward-looking statements contained in this press release, including, without limitation, risks associated with: the ability of each party to perform its obligations under the Kymera and Gilead exclusive option and license agreement, whether the parties will be able to successfully conduct and complete preclinical development, clinical development and commercialization of any drug candidates under the Kymera and Gilead collaboration, the unexpected emergence of adverse events or other undesirable side effects during preclinical and clinical development, whether Kymera will be able to fund development activities and achieve development goals, including those under the Kymera and Gilead collaboration, risks and uncertainties relating to the timing and receipt of payments from Kymera's collaboration partners, including milestone payments and royalties on future potential product sales, the availability and timing of data from future clinical trials and the results of such trials, the ability to successfully demonstrate the safety and efficacy of drug candidates, the timing and outcome of planned interactions with and submissions to regulatory authorities, the availability of funding sufficient for our operating expenses and capital expenditure requirements and other factors. These risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Kymera‘s most recent Quarterly Report on Form 10-Q and in subsequent filings with the Securities Exchange Commission. In addition, any forward-looking statements represent Kymera's views only as of today and should not be relied upon as representing Kymera‘s views as of any subsequent date. Kymera explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

    Availability of Other Information About Kymera Therapeutics

    For more information, please visit the Kymera website at https://www.kymeratx.com/ or follow Kymera on X (@KymeraTx) and LinkedIn (Kymera Therapeutics). Investors and others should note that Kymera communicates with its investors and the public using the Company website, including, but not limited to, corporate disclosures, investor presentations, FAQs, Securities and Exchange Commission (SEC) filings, and press releases, as well as on X and LinkedIn. The information that Kymera posts on its website or on X or LinkedIn could be deemed to be material information. As a result, Kymera encourages investors, the media and others interested to review the information that Kymera posts there on a regular basis. The contents of Kymera's website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

    Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies. The Kymera name and logo are trademarks of Kymera.

    For more information about Gilead, please visit the company's website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250625261668/en/

    Gilead Info

    Jessica Smith, Media

    [email protected]



    Jacquie Ross, Investors

    [email protected]

    Kymera Therapeutics Info

    Justine Koenigsberg

    Vice President, Investor Relations

    [email protected]

    [email protected]

    857-285-5300

    Get the next $GILD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GILD
    $KYMR

    CompanyDatePrice TargetRatingAnalyst
    Kymera Therapeutics Inc.
    $KYMR
    9/18/2025$60.00 → $70.00Buy
    H.C. Wainwright
    Kymera Therapeutics Inc.
    $KYMR
    9/17/2025$60.00Overweight
    Barclays
    Kymera Therapeutics Inc.
    $KYMR
    9/16/2025$70.00Outperform
    RBC Capital Mkts
    Gilead Sciences Inc.
    $GILD
    8/19/2025$128.00Neutral → Outperform
    Daiwa Securities
    Gilead Sciences Inc.
    $GILD
    8/8/2025$127.00Hold → Buy
    Truist
    Kymera Therapeutics Inc.
    $KYMR
    7/30/2025$60.00Buy
    B. Riley Securities
    Gilead Sciences Inc.
    $GILD
    7/25/2025$133.00Hold → Buy
    Needham
    Kymera Therapeutics Inc.
    $KYMR
    7/3/2025$70.00Overweight
    Morgan Stanley
    More analyst ratings

    $GILD
    $KYMR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman & CEO O'Day Daniel Patrick sold $1,116,564 worth of shares (10,000 units at $111.66), decreasing direct ownership by 2% to 591,203 units (SEC Form 4)

    4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    9/30/25 4:57:47 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by SVP, Controllership Burkhart Erin

    4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    9/23/25 7:55:57 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Burkhart Erin

    3 - GILEAD SCIENCES, INC. (0000882095) (Issuer)

    9/23/25 7:53:59 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    $KYMR
    SEC Filings

    View All

    SEC Form 144 filed by Kymera Therapeutics Inc.

    144 - Kymera Therapeutics, Inc. (0001815442) (Subject)

    9/17/25 4:24:12 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Gilead Sciences Inc.

    144 - GILEAD SCIENCES, INC. (0000882095) (Subject)

    9/15/25 4:04:03 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kymera Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)

    9/3/25 7:10:20 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    $KYMR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright reiterated coverage on Kymera Therapeutics with a new price target

    H.C. Wainwright reiterated coverage of Kymera Therapeutics with a rating of Buy and set a new price target of $70.00 from $60.00 previously

    9/18/25 7:49:23 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Barclays initiated coverage on Kymera Therapeutics with a new price target

    Barclays initiated coverage of Kymera Therapeutics with a rating of Overweight and set a new price target of $60.00

    9/17/25 8:02:47 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    RBC Capital Mkts initiated coverage on Kymera Therapeutics with a new price target

    RBC Capital Mkts initiated coverage of Kymera Therapeutics with a rating of Outperform and set a new price target of $70.00

    9/16/25 8:08:48 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    $KYMR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

    11/15/24 4:36:27 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    $KYMR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gilead Foundation Grants $6.5 Million in Commitment to STEM Education

    --Combined Funding Strengthens Bay Area Community with STEM Curriculum, Building Scientific, Technology and Mathematics Literacy-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that it has committed more than $6.5 million in grant funding toward strengthening science, technology, engineering and math (STEM) education pathways in the San Francisco Bay Area and beyond. The funding, distributed through the Gilead Foundation, will build on the company's ongoing work to cultivate a robust talent pipeline comprised of students from a broad spectrum of backgrounds and experiences. These donations represent an ongoing commitment to supporting organizations where Gilead colleagues live and

    9/25/25 8:00:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374 and Continued Development of In Vivo Hematopoietic Stem Cell Engineering Pipeline

    Company's Phase 1/2 Clinical Trial of EN-374 in X-linked Chronic Granulomatous Disease is Now Open for Patient Enrollment Ensoma, an in vivo hematopoietic stem cell (HSC) engineering company with a mission to advance the future of medicine through one-time therapies, today announced the closing of a $53 million financing from its existing syndicate of top-tier investors. The financing will support Ensoma's recently initiated Phase 1/2 clinical trial for EN-374 in X-linked chronic granulomatous disease (X-CGD) and support key clinical readouts, while continuing to expand and refine the potential global impact of the company's in vivo engineered cell therapy platform in immuno-oncology and

    9/22/25 7:00:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

    – PEPFAR, Coordinated by the U.S. State Department, will Support Delivery of Lenacapavir for PrEP in High-Incidence, Resource-Limited Countries as Key Part of Strategic Efforts with Global Fund to Accelerate Access – Gilead Sciences, Inc. (NASDAQ:GILD) today announced a partnership with the U.S. State Department and the United States President's Emergency Plan for AIDS Relief (PEPFAR) to deliver lenacapavir—Gilead's twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). This is a key component of Gilead's larger coordinated efforts, now bringing together the resources and expertise of both PEPFAR and the Global Fund, to further advance

    9/4/25 2:15:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    $KYMR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bvf Partners L P/Il bought $13,955,348 worth of shares (317,167 units at $44.00) (SEC Form 4)

    4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

    7/1/25 6:41:37 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Baker Bros. Advisors Lp bought $28,842,000 worth of shares (655,500 units at $44.00) (SEC Form 4)

    4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

    6/30/25 8:15:05 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Baker Bros. Advisors Lp bought $46 worth of shares (1 units at $46.41) (SEC Form 4)

    4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)

    8/22/24 4:03:26 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    $KYMR
    Financials

    Live finance-specific insights

    View All

    Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

    – PEPFAR, Coordinated by the U.S. State Department, will Support Delivery of Lenacapavir for PrEP in High-Incidence, Resource-Limited Countries as Key Part of Strategic Efforts with Global Fund to Accelerate Access – Gilead Sciences, Inc. (NASDAQ:GILD) today announced a partnership with the U.S. State Department and the United States President's Emergency Plan for AIDS Relief (PEPFAR) to deliver lenacapavir—Gilead's twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). This is a key component of Gilead's larger coordinated efforts, now bringing together the resources and expertise of both PEPFAR and the Global Fund, to further advance

    9/4/25 2:15:00 PM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention

    – Yeytuo® is the First and Only European Commission (EC)-Authorized HIV PrEP Option Offering 6 Months of Protection – – Accelerated EC Decision Comes After U.S. FDA Approval in June – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted marketing authorization for Yeytuo® (lenacapavir)—the company's twice-yearly injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents with increased HIV-1 acquisition risk who weigh at least 35kg. Yeytuo is the first and only twice-yearly PrEP option to be approved for use in the European Union's 27 member states, as we

    8/26/25 3:00:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update

    Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients on track to report data in 4Q25 Doses selected for KT-621 Phase 2b trials in AD and asthma, which are on track to initiate in 4Q25 and 1Q26, respectively KT-579 (IRF5) IND-enabling studies ongoing, with Phase 1 clinical trial expected to start in early 2026 Company entered a strategic partnership with Gilead to develop novel oral molecular glue CDK2 degraders, with up to $750 million in potential total payments

    8/11/25 7:00:00 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    $KYMR
    Leadership Updates

    Live Leadership Updates

    View All

    Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary

    WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Brian Adams, JD, as Chief Legal Officer and Corporate Secretary. Mr. Adams is a highly accomplished legal executive with nearly two decades of leadership in the life sciences, spanning corporate development, strategic planning, and governance. He will lead Kymera's legal, governance, and intellectual property functions. Mr. Adams will succeed Ellen Chiniara who is retiring from her role to focus on board service, mentoring and oth

    9/3/25 7:00:00 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025

    WATERTOWN, Mass., May 30, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will announce results from the Phase 1 clinical trial evaluating single and multiple-ascending doses of KT-621 in healthy volunteers on Monday, June 2, 2025. The Company will host a video webcast at 8:00 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A replay of the webcast and copy of the presentation will be a

    5/30/25 4:01:00 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Kymera Therapeutics Expands Industry Leading Immunology Pipeline with New First-in-Class, Oral IRF5 Degrader Program with Potential to Address Multiple Immuno-Inflammatory Diseases

    IRF5 program strengthens Kymera's oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a historically undrugged transcription factor and master regulator of immunity, has strong genetic and clinical pathway validation across multiple diseases including RA, SLE, IBD and others KT-579, a potent, selective, oral degrader of IRF5 with an excellent profile in preclinical safety studies, has demonstrated activity comparable or superior to approved and clinically active drugs in multiple efficacy animal models of lupus and RA IND-enabling studies are ongoing with Phase 1 testing expected to

    5/9/25 7:01:00 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $GILD
    $KYMR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

    SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

    11/14/24 4:31:20 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

    SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

    11/14/24 1:22:39 PM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kymera Therapeutics Inc.

    SC 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)

    11/14/24 9:30:22 AM ET
    $KYMR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care